This is not your typical blog. We have recruited scholars and public policy analysts from around the world to provide daily news and commentary on the implications of bioethical issues for women. We hope you’ll bookmark this page and let us know what you think: just click on the comment link at the bottom of each post to join the discussion. To sign up for the WBP newsletter, visit our homepage at www.womensbioethics.org or follow us on Twitter at http://twitter.com/khinsch

Disclaimer: The opinions expressed on this blog are solely those of the individual contributors and do not necessarily reflect the official policy positions of the Women's Bioethics Project.

Tuesday, February 10, 2009

Women and girls are the new face of HIV/AIDS. Globally, there are twelve HIV-positive women for every ten HIV-positive men. In the hardest hit countries of sub-Saharan Africa, young women are three times more likely than their male peers to become infected.

The disproportionate impact of HIV on women is due to a variety of biological and socioeconomic factors, factors that also make current HIV prevention tools – including condoms and mutual monogamy – inaccessible to those most at risk. For example, many women do not have the social or economic power necessary to insist on condom use and fidelity, or to abandon partnerships that put them at risk.

Thus, there is a desperate need to develop new user-controlled tools to enable women to protect themselves, such as vaginal microbicides. Over the past two years, a series of flat findings and trial closures have shaken public confidence in research to develop safe and effective microbicides. But now there’s a glimmer of hope.

This study enrolled over 3000 at-risk women in Malawi, South Africa, United States, Zambia and Zimbabwe. In addition to showing that these products were safe to use, the study found that women used PRO2000 (as a topically-applied gel) plus condoms had 30% fewer HIV infections than those who used only condoms or condoms plus a placebo gel.

Although the decrease in HIV infections among women using PRO2000 did not quite achieve statistical significance, this is first large-scale clinical trial showing that a candidate microbicide might actually work in women. A second trial of PRO2000, enrolling more than 9000 at-risk women in Southern Africa, is currently underway. The results of that study – known as MDP201 – will be available in November. If the data from the MDP201 trial also show that PRO2000 is safe and effective, it is expected that this gel will be submitted for regulatory review and approval, hopefully giving women worldwide access to a new and sorely needed HIV prevention tool.

VerveEarth

Contact Mailer

Nature Ally

Blog Disclaimer

The opinions expressed on this website are solely those of the contributors, and are NOT representative in any way of their employers or the Women's Bioethics Project.

The authors retain all copyright through the terms of the Creative Commons license on the site, and thus may use or publish any post elsewhere in compliance with U.S. copyright law. The information on this site is intended for educational discussion purposes only, and not as recommendations on how to diagnose or treat illnesses.

Nothing on this website constitutes legal, medical, or other professional advice. In addition, nothing on this blog serves to create any kind of professional relationship whatsoever.

No confidential patient or research subject information held by any author of any posting will be placed on the blog, nor should any information you post in comments or email written to the authors or managers of the blog, authors of its postings, in comments, to management, or to our design or technical support staff be considered confidential. Do not post or otherwise utilize confidential information of any kind on this site.